Why Amicus Therapeutics (FOLD) Stock Is Surging Today

NEW YORK (TheStreet) -- Amicus Therapeutics  (FOLD) surged Tuesday after the company announced its lead drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.

Amicus found the drug effective in patients after 12 months of treatment in the trial, which tested migalastat as a form of monotherapy in patients with Fabry disease, a disorder in which a fat called globotriaosylceramide builds up in the body's cells. The company also released positive 24-month data. 

"Today is a great day for Amicus and the Fabry community," said Chairman and CEO John F. Crowley in a statement. "Pending positive data from our second Phase 3 study we expect to meet with regulatory authorities to discuss these data and determine the fastest registration pathway for migalastat."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 21.74% to $2.24 at 2:04 p.m.

FOLD Chart

FOLD data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1